China Resources Pharmaceutical's Affiliate Completes Issuance of RMB 2 Billion in 2026 Corporate Bonds (Tranche III)

(Zhitong Finance APP) CR PHARMA COMM (03320) announced that its non-wholly-owned subsidiary, China Resources Pharmaceutical Commercial Group Co., Ltd. ("CR Pharma Commercial"), has completed the public issuance of the third tranche of its 2026 corporate bonds in China. The third tranche of the 2026 corporate bonds, with a principal amount of RMB 2 billion, has been issued with a term of three years and an annual coupon rate of 1.59%. The net proceeds raised from the issuance of the third tranche of the 2026 corporate bonds will be used for productive expenditures, including supplementing working capital, repaying interest-bearing debts, project investments, and other purposes compliant with applicable laws and regulations.